Results 41 to 50 of about 5,773 (216)

Bioavailability of chlorpropamide. [PDF]

British Journal of Clinical Pharmacology, 1979
1. The serum profiles of chlorpropamide obtained following single doses of two tablet preparations and from a suspension formulation have been compared in healthy volunteers. The amounts of chlorpropamide absorbed from the three formulations were similar but the drug was absorbed more rapidly from the suspension than from either tablet formulation ...
RC Glass, BM Munday, M Evans, R Yates, M Mitchard   +4 more
openaire   +3 more sources

Comparative study of the hypoglycemic and biochemical effects of Catharanthus roseus (Linn) g. apocynaceae (Madagascar periwinkle) and chlorpropamide (diabenese) on alloxan-induced diabetic rats [PDF]

, 2005
The effect of the aqueous extracts of Catharanthus roseus and chlorpropamide (Diabenese) on the levels of serum cholesterol, total protein, lipid peroxidation, blood glucose and liver enzymes were compared in alloxan-induced diabetic rats.
Iweala, E. E. J., Okeke, C. U.
core   +1 more source

Association between chronic diseases and severe periodontal disease progression: A retrospective cohort study in a city of Japan

Journal of General and Family Medicine, Volume 26, Issue 1, Page 54-64, January 2025.
This manuscript is a study demonstrating the association between the progression of severe periodontal diseases and chronic diseases commonly addressed in primary care. We used claims data and defined the outcome as the “progression of severe periodontitis” and followed patients for 4 years.
Sayaka Nin, Yu Sun, Takami Maeno, Chihiro Nishiura, Kento Taira, Kenji Fujimoto, Jun Hamano, Sachiko Ozone, Tetsuhiro Maeno   +8 more
wiley   +1 more source

Therapeutic challenge: Unusual coexistence of idiopathic central diabetes insipidus and diabetes mellitus in a male with vitiligo

Caspian Journal of Internal Medicine, 2021
Background: Idiopathic central diabetes insipidus (DI) is a rare endocrine disorder that results from total or partial deficiency of vasopressin secretion.
Diego Moreno Marreros, Marcio José Concepción Zavaleta, Eilhart Jorge Garxia Villasante, Esteban Alberto Plasencia Dueñas, Sofia Ildefonso Najarro, José Carrion Rojas, Carmen Luisa Achahui Acurio   +6 more
doaj  

Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions

Cardiovascular Diabetology, 2007
Background Inhibition of vascular smooth muscle cell (vSMC) proliferation by oral anti-hyperglycemic agents may have a role to play in the amelioration of vascular disease in diabetes.
de Dios Stephanie T, Osman Narin, Little Peter J, Cemerlang Nelly, Ballinger Mandy, Nigro Julie   +5 more
doaj   +1 more source

Medications and Acute Hemolysis in G6PD‐Deficient Patients – A Real‐World Study

Clinical Pharmacology &Therapeutics, Volume 116, Issue 6, Page 1537-1543, December 2024.
Many drug labels contain precautions of use in G6PD‐deficient patients due to hemolytic concerns, but much of this is based on scarce clinical, epidemiological, or structural data. In this real‐world study, we aimed to examine if the administration of presumably risky medications for G6PD‐deficient patients was followed by hemolysis. The study is based
Naomi Gronich, Bar Rosh, Nili Stein, Walid Saliba   +3 more
wiley   +1 more source

Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study

Diabetes, Obesity and Metabolism, Volume 26, Issue 11, Page 5408-5419, November 2024.
Abstract Aim To examine the likelihood of mortality or rehospitalization following acute coronary syndrome with glyburide versus gliclazide use in adults with type 2 diabetes undergoing cardiac catheterization. Research Design and Methods This retrospective cohort study used clinical data linked with administrative health data from Alberta, Canada ...
Wentong Long, Peter E. Light, Scot H. Simpson   +2 more
wiley   +1 more source

Metabolomic identification of predictive and early biomarkers of cisplatin‐induced acute kidney injury in adult head and neck cancer patients

British Journal of Clinical Pharmacology, Volume 90, Issue 8, Page 1790-1803, August 2024.
Aim Cisplatin causes acute kidney injury (AKI) in approximately one third of patients. Serum creatinine and urinary output are poor markers of cisplatin‐induced AKI. Metabolomics was utilized to identify predictive or early diagnostic biomarkers of cisplatin‐induced AKI.
Yong Jin Lim, Steven G. Xiu, M. Sara Kuruvilla, Eric Winquist, Stephen Welch, Morgan Black, Lauren N. Faught, Jasmine Lee, Michael J. Rieder, Tom D. Blydt‐Hansen, Michael Zappitelli, Bradley L. Urquhart   +11 more
wiley   +1 more source

Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin

Diabetes, Obesity and Metabolism, Volume 26, Issue S3, Page 55-74, August 2024.
Abstract Evidence‐based guidelines provide the premise for the delivery of quality care to preserve health and prevent disabilities and premature death. The systematic gathering of observational, mechanistic and experimental data contributes to the hierarchy of evidence used to guide clinical practice. In the field of diabetes, metformin was discovered
Juliana C. N. Chan, Aimin Yang, Natural Chu, Elaine Chow   +3 more
wiley   +1 more source

Treatment of Diabetes With Oral Hypoglycemic Drugs [PDF]

, 1966
Oral hypoglycemic drugs now available are of two types. The biguanides, of which phenformin (DBI) is the only one available, increase glucose utilization by muscles.
Moss, James M.
core   +1 more source